Timeline reforms increase initiation speed of NCI sponsored clinical trials

June 17, 2013

The National Cancer Institute (NCI) and investigators have reduced the deadlines for initiation of trials with the goal of reaching more patients in need of new treatments, according to a study published June 17 in the Journal of the National Cancer Institute.

In the year 2008, the NCI created the Operational Efficiency Working Group (OWEG) to develop recommendations for increasing the speed at which NCI-sponsored are initiated. An approach to mobilize and improve business processes among the research community was devised that included new staff positions, protocols, and planned conference calls between the NCI staff and the investigator teams. These measures were implemented to ultimately meet new target timelines and deadlines for initiation of phase 1-2 and 3 studies by eliminating redundant efforts and rapidly resolving critical issues quickly. For phase 1-2 studies, the target timeline was set as 7 months and the absolute deadline was18 months. For studies, the target timeline was 10 months and the absolute deadline was 24 months. If a trial was not initiated by the absolute deadline, it was automatically disapproved.

Jeffrey S. Abrams, M.D., from the , Division of and Diagnosis at the NCI in Bethesda, Maryland, and colleagues compared trial initiation times before and after implementation of the OEGW recommendations. A total of 525 pre-OEWG trials and 152 post-OEWG phase 1-2 trials were included in the analysis, whereas 112 pre-OEWG trials and 24 post-OEWG phase 3 trials were included.

The researchers found that the median time to activation of phase 1-2 trials decreased from 541 to 442 days. Similarly, the median time to activation of phase 3 trials decreased from 727 to 395 days, and none of the 25 trials included in the analysis reached or went beyond the predetermined absolute deadline of 730 days. These results provide evidence that the implementation of the OEWG recommendations have led to more rapid initiation of NCI-sponsored trials, ultimately benefiting patients in need of new treatments for cancer. The authors conclude, "improvements in trial initiation should encourage potential partners in the pharmaceutical and biotechnology industries to view the NCI's publicly funded clinical trials system as a place where their new agent or device can be rapidly moved into the clinic."

Explore further: Greater representation of elderly patients in Phase III trials are needed

Related Stories

Greater representation of elderly patients in Phase III trials are needed

February 22, 2013
The median age of patients diagnosed with advanced non–small-cell lung cancer (NSCLC) has steadily increased over the recent years and is presently 70 years. Despite this, the elderly are significantly underrepresented ...

Molecular 'portraits' of tumours match patients with trials in everyday clinical practice

November 8, 2012
Researchers in France are taking advantage of the progress in genetic and molecular profiling to analyse the make-up of individual cancer patients' tumours and, using this information, assign them to particular treatments ...

AACR releases policy guidance on tobacco and cancer clinical trials

April 10, 2013
An American Association for Cancer Research (AACR) statement calls on the oncology community to provide evidence-based tobacco cessation treatment for all cancer and cancer-screening patients and to evaluate tobacco as a ...

Experimental drug beneficial in NIH trial to treat a rare sarcoma

May 7, 2013
(Medical Xpress)—Patients with advanced alveolar soft part sarcoma (ASPS), a rare cancer, achieved some control of their disease using an experimental anti-cancer drug called cediranib. The results from this largest clinical ...

Cancer biorepository speeds clinical trials, drug development, analysis shows

May 8, 2013
Researchers at Moffitt Cancer Center say identifying and selecting participants for phase II cancer clinical trials from a centralized warehouse of patient-donated biological data expedites participant accrual, reduces trial ...

Recommended for you

A metabolic treatment for pancreatic cancer?

August 15, 2017
Pancreatic cancer is now the third leading cause of cancer mortality. Its incidence is increasing in parallel with the population increase in obesity, and its five-year survival rate still hovers at just 8 to 9 percent. Research ...

Skewing the aim of targeted cancer therapies

August 15, 2017
Headlines, of late, have touted the successes of targeted gene-based cancer therapies, such as immunotherapies, but, unfortunately, also their failures.

Findings pave way for three-drug combination treatment for childhood leukemia

August 15, 2017
UCLA researchers have developed a new approach that could eventually help young people respond better to treatment for acute lymphoblastic leukemia. The scientists discovered in mice that when the production of nucleotides—also ...

Does stronger initial response to cancer treatment predict longer overall survival?

August 15, 2017
It seems like such a simple question: Do patients whose tumors shrink more in response to targeted treatment go on to have better outcomes than patients whose tumors shrink less? Actually, the answer seems simple too. In ...

New study reveals late spread of breast cancer and backs key role of early diagnosis

August 14, 2017
Breast cancer cells that spread to other parts of the body break off and leave the primary tumour at late stages of disease development, scientists from the Wellcome Trust Sanger Institute and their collaborators have found.

Discovery of new prostate cancer biomarkers could improve precision therapy

August 14, 2017
Mayo Clinic researchers have identified a new cause of treatment resistance in prostate cancer. Their discovery also suggests ways to improve prostate cancer therapy. The findings appear in Nature Medicine. In the publication, ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.